BAC
Bank of America Corporation
BAC has the edge over FISI overall, supported by stronger valuation and stronger fundamentals.
FISI
Financial Institutions, Inc.
FISI's outlook is improving, though it still trails on the overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
FISI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| N/A | |
| N/A |
FISI's profitability is currently strong. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like FISI.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over FISI in the historical PE scenario, which offers more potential upside but is not a forecast.
FISI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.8x | $23.28 | -42% |
| Fair | 7.3x | $29.54 | -26% |
| Forward | 9.5x | $40.04 | — |
| Expensive | 9.9x | $39.80 | -0.6% |
| Current | 9.9x | $40.04 | — |
Historical ranges are pointers, not guarantees.
FISI's PE is in its expensive range at 9.9x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over FISI on the outlook, with more favorable valuation expectations.
FISI Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for FISI, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
FISI has the stronger earnings trend. Trailing diluted EPS is up 14% for BAC versus FISI up 27%.
FISI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.24 | +5.1% |
| Q3 2024 | $3.17 | -4.2% |
| Q2 2024 | $3.21 | -3% |
| Q1 2024 | $2.50 | -26% |
| Q4 2023 | $3.15 | -12% |
| Q3 2023 | $3.31 | -17% |
| Q2 2023 | $3.31 | -21% |
| Q1 2023 | $3.39 | -24% |
| Q4 2022 | $3.56 | -26% |
FISI earned $4.03 per share over the past year, up 27% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over FISI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
FISI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.7M | +1.4% |
| Q2 2026 | $64.3M | +7.7% |
| Q1 2026 | $62.7M | +9.5% |
| Q3 2025 | $63.8M | +27% |
| Q2 2025 | $59.7M | -8.4% |
| Q1 2025 | $57.2M | +12% |
| Q3 2024 | $50.1M | -3.9% |
| Q2 2024 | $65.2M | +21% |
FISI's revenue has grown year over year for four quarters in a row: $65M last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | -2.4 points |
| Q2 2026 | 40% | +3.8 points |
| Q1 2026 | 40% | +3.6 points |
| Q4 2025 | 37% | N/A |
| Q3 2025 | 40% | +11 points |
| Q2 2025 | 36% | -10 points |
| Q1 2025 | 36% | +31 points |
| Q3 2024 | 29% | -2.5 points |
FISI has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
FISI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $31.8M | +$39.7M |
| Q2 2026 | $21.8M | +$29.1M |
| Q1 2026 | $23M | +151% |
| Q3 2025 | -$7.9M | -$7.6M |
| Q2 2025 | -$7.3M | -121% |
| Q1 2025 | $9.2M | -17% |
| Q3 2024 | -$299K | -101% |
| Q2 2024 | $34.7M | +341% |
FISI has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over FISI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
FISI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -39K shares |
| 1 year | -2.1% | -434K shares |
| 3 years | +29% | +4.5M shares |
| 5 years | +25% | +4M shares |
| Available history | +24% | +3.9M shares |
FISI has 20M diluted shares, down 2.1% from a year ago, with $25M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.7M |
| Q2 2026 | $65,000 |
| Q1 2026 | $6.1M |
| Q4 2025 | $10.9M |
| Q3 2025 | $34,000 |
| Q2 2025 | — |
| Q1 2025 | $481,000 |
| Q3 2024 | $26,000 |
FISI spent $25M buying back its own shares over the past year.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
FISI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.3x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 2.0x | Healthy |
| Q3 2024 | -1.0x | Net Cash |
| Q2 2024 | 2.5x | Moderate |
| Q1 2024 | 0.4x | Very low |
| Q4 2023 | 2.6x | Moderate |
FISI has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
FISI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.7 | Neutral |
| Stochastic | 38.7 | Neutral |
FISI's weekly RSI is 57 (neutral) and its Stochastic is 39 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
FISI PE vs Financial Services Sector
| Metric | FISI | Sector median | Relative |
|---|---|---|---|
| PE | 9.9x | 13x | 24% below |
| PE % | 84 | 63 | 21 pts above |
FISI has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
FISI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.7 | 0.8% above |
| 20 week MA | $40.3 | 0.6% below |
| 50 week MA | $36.2 | 11% above |
| 100 week MA | $31.4 | 28% above |
| 200 week MA | $25.8 | 55% above |
FISI has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
FISI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.0 | $22.5 | -30% |
| 2021 | $22.5 | $31.8 | +42% |
| 2022 | $31.8 | $24.5 | -23% |
| 2023 | $24.5 | $21.3 | -13% |
| 2024 | $21.3 | $27.0 | +27% |
| 2025 | $27.0 | $32.0 | +18% |
| 2026 YTD | $32.0 | $40.0 | +25% |
FISI has the edge over BAC on returns for 2026, with the stronger performance.